Invicta Diagnostic launches tele-radiology in US

Invicta Diagnostic Limited has expanded its operations by launching tele-radiology services in the United States. The company announced on May 22, 2026, that it has commenced reporting for clients in the U.S., marking its first step into the international market. This strategic move is intended to support the company's global growth objectives while maintaining its commitment to high-quality diagnostic reporting.

The newly launched services aim to enhance patient care by providing timely and accurate diagnostic reports to a broader healthcare network. By extending its reach beyond India, invicta diagnostic seeks to leverage its expertise in tele-radiology to serve international clients effectively.

Service Details

The expansion focuses on the delivery of diagnostic services specifically tailored for the international market. The key details of the product launch are outlined below:

Aspect	Details
Name of the product	Tele-Radiology services
Date of launch	22-05-2026
Category of the product	Diagnostic Services
Market catered to	International Market
Country of launch	United States of America

This development represents a significant milestone in the company's history as it begins to cater to clients abroad. The management believes that this initiative will strengthen its market position and contribute to the overall growth of the organization.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-4.98%	-25.31%	-17.32%	-30.87%	-30.87%	-30.87%

Invicta Diagnostic Limited has completed the sale of its 47% stake in Porteus Medical LLP. The company executed the third supplementary LLP agreement on May 16, 2026, finalizing the transaction that was initially intimated to the exchanges on January 05, 2026.

The sale consideration amounted to ₹47000. The buyers included Dr. Vishwajeet Arvind Burungale, Dr. Aniruddha Joshi, Dr. Girish Govindrao Kakde, and Dr. Shriganesh Patil, all of whom are radiologists. The company confirmed that none of the buyers belong to the promoter group or group companies.

Financial Details of Subsidiary

According to the disclosures, Porteus Medical LLP reported a turnover of Rs. NIL for the financial year 2024-25. The net worth of the entity as on March 31, 2025, stood at Rs. 1.25 Lakhs, which represented 0.07% of the consolidated net worth of Invicta Diagnostic Limited.

Particulars	Details
Stake Sold	47%
Consideration Received	₹47000
Date of Agreement	May 16, 2026
Date of Completion	May 16, 2026
Turnover FY 2024-25	Rs. NIL
Net Worth (March 31, 2025)	Rs. 1.25 Lakhs

Transaction Compliance

The company stated that the transaction does not fall within related party transactions and was not conducted at arm's length. As the sale constitutes 0.07% of the consolidated net worth of the company, which is less than 20%, the compliance requirements under regulation 37A of the LODR Regulations are not applicable. The disclosures regarding the sale have been uploaded to the company's website.